|
2026-06-04 |
2026-06-03 |
V
Vente
|
Head of Regulatory
Dirigeant
|
79 824
+11.0%
479,25
3 554 848 $US
|
79 824
+11.0%
|
479,25
|
3 554 848 $US
|
|
|
2026-06-02 |
2026-06-01 |
PlS
Vente planifiée
|
Administrateur non-exécutif
|
54 923
-19.7%
234,98
1 971 300 $US
|
54 923
-19.7%
|
234,98
|
1 971 300 $US
|
|
|
2026-06-01 |
2026-06-01 |
PrS
Vente proposée
|
Officer
Dirigeant
|
76 198
425,29
142 243 $US
|
76 198
|
425,29
|
142 243 $US
|
|
|
2026-05-12 |
2026-05-11 |
V
Vente
|
Head of Regulatory
Dirigeant
|
270
-0.4%
2,98
804 $US
|
270
-0.4%
|
2,98
|
804 $US
|
|
|
2026-05-12 |
2026-05-11 |
V
Vente
|
President and CEO
Dirigeant
|
2 798
-0.5%
2,94
8 226 $US
|
2 798
-0.5%
|
2,94
|
8 226 $US
|
|
|
2026-05-12 |
2026-05-11 |
V
Vente
|
Chief Technical Officer
Dirigeant
|
605
-0.4%
2,97
1 799 $US
|
605
-0.4%
|
2,97
|
1 799 $US
|
|
|
2026-05-12 |
2026-05-11 |
V
Vente
|
Chief Scientific Officer
Dirigeant
|
605
-0.4%
2,97
1 798 $US
|
605
-0.4%
|
2,97
|
1 798 $US
|
|
|
2026-03-26 |
2026-03-25 |
V
Vente
|
Head of Regulatory
Dirigeant
|
240
-0.4%
2,51
602 $US
|
240
-0.4%
|
2,51
|
602 $US
|
|
|
2026-03-26 |
2026-03-24 |
V
Vente
|
SVP, Clinical Development
Dirigeant
|
906
-0.6%
2,42
2 193 $US
|
906
-0.6%
|
2,42
|
2 193 $US
|
|
|
2026-03-26 |
2026-03-24 |
V
Vente
|
Chief Technical Officer
Dirigeant
|
906
-0.6%
2,42
2 193 $US
|
906
-0.6%
|
2,42
|
2 193 $US
|
|
|
2026-03-26 |
2026-03-24 |
V
Vente
|
Head of Regulatory
Dirigeant
|
345
-0.5%
2,42
835 $US
|
345
-0.5%
|
2,42
|
835 $US
|
|
|
2026-03-26 |
2026-03-24 |
V
Vente
|
President and CEO
Dirigeant
|
3 582
-0.7%
2,42
8 668 $US
|
3 582
-0.7%
|
2,42
|
8 668 $US
|
|
|
2026-03-03 |
2026-03-02 |
PlS
Vente planifiée
|
Administrateur non-exécutif
|
10 000
-2.0%
2,90
28 957 $US
|
10 000
-2.0%
|
2,90
|
28 957 $US
|
|
|
2026-03-02 |
2026-03-02 |
PrS
Vente proposée
|
Officer
Dirigeant
|
10 000
2,98
29 800 $US
|
10 000
|
2,98
|
29 800 $US
|
|
|
2025-12-09 |
2025-12-05 |
V
Vente
|
Head of Regulatory
Dirigeant
|
165
-0.2%
4,69
774 $US
|
165
-0.2%
|
4,69
|
774 $US
|
|
|
2025-12-02 |
2025-12-01 |
PlS
Vente planifiée
|
Administrateur non-exécutif
|
10 000
-2.0%
5,00
50 008 $US
|
10 000
-2.0%
|
5,00
|
50 008 $US
|
|
|
2025-12-01 |
2025-12-01 |
PrS
Vente proposée
|
Director
Administrateur non-exécutif
|
10 000
5,56
55 600 $US
|
10 000
|
5,56
|
55 600 $US
|
|
|
2025-12-11 |
2025-11-17 |
V
Vente
|
SVP, Clinical Development
Dirigeant
|
973
-0.7%
5,37
5 224 $US
|
973
-0.7%
|
5,37
|
5 224 $US
|
|
|
2025-12-11 |
2025-11-17 |
PlS
Vente planifiée
|
President and CEO
Dirigeant
|
4 509
-0.8%
5,37
24 211 $US
|
4 509
-0.8%
|
5,37
|
24 211 $US
|
|
|
2025-12-11 |
2025-11-17 |
V
Vente
|
Chief Technical Officer
Dirigeant
|
973
-0.6%
5,37
5 224 $US
|
973
-0.6%
|
5,37
|
5 224 $US
|
|
|
2025-12-09 |
2025-11-17 |
V
Vente
|
Head of Regulatory
Dirigeant
|
343
-0.5%
5,37
1 842 $US
|
343
-0.5%
|
5,37
|
1 842 $US
|
|
|
2025-12-09 |
2025-09-03 |
V
Vente
|
Head of Regulatory
Dirigeant
|
580
-0.8%
3,36
1 948 $US
|
580
-0.8%
|
3,36
|
1 948 $US
|
|
|
2025-12-11 |
2025-08-21 |
V
Vente
|
SVP, Clinical Development
Dirigeant
|
3 219
-2.1%
3,36
10 807 $US
|
3 219
-2.1%
|
3,36
|
10 807 $US
|
|
|
2025-12-11 |
2025-08-21 |
PlS
Vente planifiée
|
President and CEO
Dirigeant
|
12 673
-2.3%
3,33
42 159 $US
|
12 673
-2.3%
|
3,33
|
42 159 $US
|
|
|
2025-12-11 |
2025-08-21 |
V
Vente
|
Chief Technical Officer
Dirigeant
|
1 463
-0.9%
3,36
4 912 $US
|
1 463
-0.9%
|
3,36
|
4 912 $US
|
|
|
2025-12-11 |
2025-08-21 |
V
Vente
|
Chief Technical Officer
Dirigeant
|
1 270
-0.8%
3,33
4 225 $US
|
1 270
-0.8%
|
3,33
|
4 225 $US
|
|
|
2025-12-09 |
2025-08-21 |
V
Vente
|
Head of Regulatory
Dirigeant
|
1 244
-1.8%
3,36
4 177 $US
|
1 244
-1.8%
|
3,36
|
4 177 $US
|
|
|
2025-05-13 |
2025-05-12 |
V
Vente
|
President and CEO
Administrateur exécutif
|
10 764
-5.3%
2,92
31 431 $US
|
10 764
-5.3%
|
2,92
|
31 431 $US
|
|
|
2025-05-13 |
2025-05-12 |
V
Vente
|
Head of Regulatory
Dirigeant
|
1 259
-3.5%
2,92
3 676 $US
|
1 259
-3.5%
|
2,92
|
3 676 $US
|
|
|
2025-05-13 |
2025-05-12 |
V
Vente
|
General Counsel
Dirigeant
|
4 475
-8.6%
2,92
13 067 $US
|
4 475
-8.6%
|
2,92
|
13 067 $US
|
|
|
2025-05-13 |
2025-05-12 |
V
Vente
|
VP, Pharmaceutical Development
Dirigeant
|
4 737
-8.3%
2,92
13 832 $US
|
4 737
-8.3%
|
2,92
|
13 832 $US
|
|
|
2025-05-13 |
2025-05-12 |
V
Vente
|
VP, Clinical Trial Operations
Dirigeant
|
5 579
-10.5%
2,92
16 291 $US
|
5 579
-10.5%
|
2,92
|
16 291 $US
|
|
|
2024-12-30 |
2024-12-30 |
PrS
Vente proposée
|
Director
Administrateur non-exécutif
|
3 460
2,46
8 512 $US
|
3 460
|
2,46
|
8 512 $US
|
|
|
2024-12-30 |
2024-12-30 |
V
Vente
|
Administrateur non-exécutif
|
3 460
-7.0%
2,46
8 512 $US
|
3 460
-7.0%
|
2,46
|
8 512 $US
|
|
|
2024-12-18 |
2024-12-16 |
PlS
Vente planifiée
|
Chief Financial Officer
Dirigeant
|
2 103
-4.9%
2,34
4 921 $US
|
2 103
-4.9%
|
2,34
|
4 921 $US
|
|
|
2024-12-18 |
2024-12-16 |
PlS
Vente planifiée
|
Head of Regulatory
Dirigeant
|
2 510
-13.3%
2,34
5 873 $US
|
2 510
-13.3%
|
2,34
|
5 873 $US
|
|
|
2024-12-18 |
2024-12-16 |
V
Vente
|
VP, Pharmaceutical Development
Dirigeant
|
6 300
-30.1%
2,34
14 742 $US
|
6 300
-30.1%
|
2,34
|
14 742 $US
|
|
|
2024-12-18 |
2024-12-16 |
PlS
Vente planifiée
|
President and CEO
Administrateur exécutif
|
14 315
-27.7%
2,34
33 497 $US
|
14 315
-27.7%
|
2,34
|
33 497 $US
|
|
|
2024-09-13 |
2024-09-13 |
V
Vente
|
Actionnaire important
|
33 080
-5.2%
2,57
84 946 $US
|
33 080
-5.2%
|
2,57
|
84 946 $US
|
|
|
2024-09-13 |
2024-09-12 |
V
Vente
|
Actionnaire important
|
31 777
-4.8%
2,73
86 732 $US
|
31 777
-4.8%
|
2,73
|
86 732 $US
|
|
|
2024-09-12 |
2024-09-11 |
PlS
Vente planifiée
|
Administrateur non-exécutif
|
1 730
-3.5%
2,60
4 499 $US
|
1 730
-3.5%
|
2,60
|
4 499 $US
|
|
|
2024-09-11 |
2024-09-11 |
PrS
Vente proposée
|
Director
Administrateur non-exécutif
|
1 730
2,51
4 342 $US
|
1 730
|
2,51
|
4 342 $US
|
|
|
2024-09-11 |
2024-09-11 |
V
Vente
|
Actionnaire important
|
31 376
-4.5%
2,62
82 227 $US
|
31 376
-4.5%
|
2,62
|
82 227 $US
|
|
|
2024-09-11 |
2024-09-10 |
V
Vente
|
Actionnaire important
|
20 384
-2.8%
2,51
51 182 $US
|
20 384
-2.8%
|
2,51
|
51 182 $US
|
|
|
2024-09-11 |
2024-09-09 |
V
Vente
|
Actionnaire important
|
23 383
-3.2%
2,70
63 200 $US
|
23 383
-3.2%
|
2,70
|
63 200 $US
|
|
|
2024-09-06 |
2024-09-09 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
140 000
2,80
392 000 $US
|
140 000
|
2,80
|
392 000 $US
|
|
|
2024-09-06 |
2024-09-03 |
V
Vente
|
Actionnaire important
|
42 818
-5.5%
2,09
89 614 $US
|
42 818
-5.5%
|
2,09
|
89 614 $US
|
|
|
2024-08-30 |
2024-08-30 |
V
Vente
|
Actionnaire important
|
142 589
-15.4%
2,17
309 846 $US
|
142 589
-15.4%
|
2,17
|
309 846 $US
|
|
|
2024-08-30 |
2024-08-29 |
V
Vente
|
Actionnaire important
|
107 045
-10.4%
1,98
211 960 $US
|
107 045
-10.4%
|
1,98
|
211 960 $US
|
|
|
2024-08-30 |
2024-08-28 |
V
Vente
|
Actionnaire important
|
15 918
-1.5%
2,05
32 605 $US
|
15 918
-1.5%
|
2,05
|
32 605 $US
|
|
|
2024-08-27 |
2024-08-27 |
V
Vente
|
Actionnaire important
|
51 630
-4.7%
2,11
108 862 $US
|
51 630
-4.7%
|
2,11
|
108 862 $US
|
|
|
2024-08-27 |
2024-08-23 |
V
Vente
|
Actionnaire important
|
40 000
-3.5%
2,29
91 416 $US
|
40 000
-3.5%
|
2,29
|
91 416 $US
|
|
|
2024-08-22 |
2024-08-23 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
400 000
2,18
872 000 $US
|
400 000
|
2,18
|
872 000 $US
|
|
|
2024-07-08 |
2024-06-24 |
V
Vente
|
VP, Clinical Trial Operations
Dirigeant
|
6 849
-38.7%
2,12
14 520 $US
|
6 849
-38.7%
|
2,12
|
14 520 $US
|
|
|
2024-07-08 |
2024-06-24 |
V
Vente
|
Head of Quality
Dirigeant
|
4 961
-23.5%
2,12
10 517 $US
|
4 961
-23.5%
|
2,12
|
10 517 $US
|
|
|
2024-07-08 |
2024-06-24 |
PlS
Vente planifiée
|
General Counsel
Dirigeant
|
5 496
-22.1%
2,12
11 652 $US
|
5 496
-22.1%
|
2,12
|
11 652 $US
|
|
|
2024-05-15 |
2024-05-15 |
V
Vente
|
Actionnaire important
|
17 094
-1.5%
3,66
62 624 $US
|
17 094
-1.5%
|
3,66
|
62 624 $US
|
|
|
2024-05-15 |
2024-05-14 |
V
Vente
|
Actionnaire important
|
15 426
-1.3%
3,58
55 274 $US
|
15 426
-1.3%
|
3,58
|
55 274 $US
|
|
|
2024-05-15 |
2024-05-13 |
V
Vente
|
Actionnaire important
|
3 446
-0.3%
3,62
12 478 $US
|
3 446
-0.3%
|
3,62
|
12 478 $US
|
|
|
2024-05-09 |
2024-05-08 |
V
Vente
|
Actionnaire important
|
13 919
-1.2%
3,82
53 189 $US
|
13 919
-1.2%
|
3,82
|
53 189 $US
|
|
|
2024-05-09 |
2024-05-07 |
V
Vente
|
Actionnaire important
|
6 025
-0.5%
3,67
22 111 $US
|
6 025
-0.5%
|
3,67
|
22 111 $US
|
|
|
2024-05-01 |
2024-05-01 |
V
Vente
|
Actionnaire important
|
33 061
-2.7%
3,30
109 161 $US
|
33 061
-2.7%
|
3,30
|
109 161 $US
|
|
|
2024-05-01 |
2024-04-30 |
V
Vente
|
Actionnaire important
|
20 535
-1.6%
3,12
63 981 $US
|
20 535
-1.6%
|
3,12
|
63 981 $US
|
|
|
2024-05-01 |
2024-04-29 |
V
Vente
|
Actionnaire important
|
6 403
-0.5%
3,25
20 792 $US
|
6 403
-0.5%
|
3,25
|
20 792 $US
|
|
|
2024-04-24 |
2024-04-24 |
V
Vente
|
Actionnaire important
|
8 064
-0.6%
3,50
28 251 $US
|
8 064
-0.6%
|
3,50
|
28 251 $US
|
|
|
2024-04-24 |
2024-04-23 |
V
Vente
|
Actionnaire important
|
22 000
-1.7%
3,49
76 800 $US
|
22 000
-1.7%
|
3,49
|
76 800 $US
|
|
|
2024-04-24 |
2024-04-22 |
V
Vente
|
Actionnaire important
|
14 331
-1.1%
3,53
50 597 $US
|
14 331
-1.1%
|
3,53
|
50 597 $US
|
|
|
2024-04-18 |
2024-04-17 |
V
Vente
|
Actionnaire important
|
22 737
-1.7%
3,71
84 425 $US
|
22 737
-1.7%
|
3,71
|
84 425 $US
|
|
|
2024-04-18 |
2024-04-16 |
V
Vente
|
Actionnaire important
|
48 683
-3.5%
3,53
171 802 $US
|
48 683
-3.5%
|
3,53
|
171 802 $US
|
|
|
2024-04-15 |
2024-04-15 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
494 744
4,25
2 102 662 $US
|
494 744
|
4,25
|
2 102 662 $US
|
|
|
2024-04-11 |
2024-04-15 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
494 744
4,25
2 102 662 $US
|
494 744
|
4,25
|
2 102 662 $US
|
|
|
2023-12-18 |
2023-12-15 |
V
Vente
|
VP, Clinical Trial Operations
Dirigeant
|
5 803
-100.0%
14,18
82 265 $US
|
5 803
-100.0%
|
14,18
|
82 265 $US
|
|
|
2023-12-18 |
2023-12-15 |
V
Vente
|
VP, Clinical Trial Operations
Dirigeant
|
26 732
-82.2%
12,94
345 915 $US
|
26 732
-82.2%
|
12,94
|
345 915 $US
|
|
|
2023-12-15 |
2023-12-15 |
PrS
Vente proposée
|
Officer
Dirigeant
|
32 535
13,16
428 180 $US
|
32 535
|
13,16
|
428 180 $US
|
|
|
2023-12-14 |
2023-12-13 |
V
Vente
|
Administrateur non-exécutif
|
1 927
-0.4%
13,93
26 839 $US
|
1 927
-0.4%
|
13,93
|
26 839 $US
|
|